Skip to content

Panbela Therapeutics (PBLA) Stock Soared 71.7% – Here’s Why

Simon Mugo trader
Updated 10 Jan 2023

The Panbela Therapeutics Inc (NASDAQ: PBLA) stock price soared 71.7% despite a lack of news from the biopharmaceutical company. Therefore, today’s rally could easily be attributed to renewed investor interest in the firm.

new-recommended-broker-banner

YOUR CAPITAL IS AT RISK. 81% OF RETAIL CFD ACCOUNTS LOSE MONEY.


In the absence of new announcements from the company, we have to look at the last significant news from the firm. A cursory look at past press releases reveals that Panbela received a positive opinion from the European Medicines Agency (EMA) regarding its SBP-101 drug candidate in December 2022.

Top Broker Recommendation

YOUR CAPITAL IS AT RISK. 68% OF RETAIL CFD ACCOUNTS LOSE MONEY

The positive opinion from the EMA’s Committee for Orphan Medicinal Products was regarding Panbela’s application for orphan designation of ivospemin, SBP-101, in combination with gemcitabine and nab-paclitaxel to treat patients with metastatic pancreatic ductal adenocarcinoma.

Jennifer K. Simpson, PhD, Panbela’s President & CEO, said: “We are pleased to receive notification of positive opinion for orphan drug designation from EMA’s Committee Orphan Medicinal Products following its December plenary meeting. The opinion is timely, as we only a few weeks ago announced the first patients enrolled in Europe in our ASPIRE trial. We continue to advance the global clinical trial as we aim for interim analysis in early 2024.”

SBP-101 had already been granted orphan drug designation by the US Food and Drug Administration (FDA) before the EMA opinion came in on December 14, 2022. 

Panbela Therapeutics had announced the enrollment of the first patients in its ASPIRE trial in Europe, with the trial expected to enrol participants globally. The trial seeks to evaluate ivospemin in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.

The ASPIRE trial will enrol 95 participants from South Korea, Europe, the United States and Australia. Panbela’s ultimate goal is to develop an effective treatment for pancreatic cancer, given the few available treatments. 

Retail investors may have finally caught on to the company’s massive potential upside if the ongoing trial is successful, given ivospemin (SBP-101’s) orphan drug status in the US and possibly in Europe. 

Over 17.56 million Panbela (PBLA) shares had changed hands at writing amid massive interest.

*This is not investment advice. 

The Panbela therapeutics (PBLA) stock price chart.

The Panbela Therapeutics (PBLA) stock price soared 71.72% to trade at $0.14, from Monday’s closing price of $0.081.


YOUR CAPITAL IS AT RISK. 81% OF RETAIL CFD ACCOUNTS LOSE MONEY.


Simon has over six years of professional trading experience across FX, commodities and equities. He has a strong passion for financial markets and is particularly focused on price action trading